Most successful animal health vaccine of all time reaches milestone of two billion pigs being protected
Worldwide over two billion pigs have been protected against Porcine Circovirus Disease using Ingelvac CircoFLEX®
The vaccine contributes to sustainable production and supply of healthy, nutritious pork around the world like no other vaccine1
Ingelheim, Germany, 26 October 2016 – Veterinarians and pig farmers were able to protect over two billion pigs around the world against Porcine Circovirus Disease using Ingelvac CircoFLEX®, the most successful animal health vaccine of all time based on yearly sales2. With more than eight pigs vaccinated every second worldwide, the vaccine contributes to sustainable production and supply of healthy, nutritious pork around the world like no other vaccine.1
“We are very proud of this milestone, and we know that it has been finally achieved by our customers – veterinarians and pig farmers around the world doing their best to prevent disease. We would like to thank them for the trust and loyalty they put into Ingelvac CircoFLEX®”, said George Heidgerken, Head of Boehringer Ingelheim Animal Health. “We continue to strive to provide the best protection against Porcine Circovirus to the global pig industry by an integrated solutions approach. This includes the supply of a high quality vaccine and tailored customer services.”
Porcine Circovirus Disease can have a devastating impact on the pigs’ health, causing suffering to the animals and economic damage to farmers. An infection with the Porcine Circovirus Type 2 (PCV 2) in unprotected pigs may lead to wasting, paleness of the skin, respiratory dysfunction (dyspnea) or diarrhoea in piglets. PCV2 can also cause medically and economically relevant subclinical infections (infections without evident clinical signs).
Ingelvac CircoFLEX® provides proven protection without compromising safety with just one shot around weaning. It is licensed to be freshly mixed with Ingelvac MycoFLEX® to protect pigs with one shot against both, PCV 2 and Mycoplasma hyopneumoniae which causes respiratory disease in pigs. Ingelvac CircoFLEX® has been recently approved to be used in sows by the European Medicines Agency.
About Boehringer Ingelheim Animal Health
Boehringer Ingelheim Animal Health is the 6th largest animal health business in the world and is committed to providing leading innovative solutions to prevent, treat and cure animal diseases. With 3,800 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about € 1.36 billion in 2015, representing 9% of the corporation’s revenue base. Main brands of Boehringer Ingelheim’s Animal Health portfolio are Ingelvac CircoFLEX® (2015 sales of € 281 million), Metacam® (2015 sales of € 101 million), Ingelvac® PRRS (2015 sales of € 99 million) and Duramune® (2015 sales of € 88 million). The Boehringer Ingelheim Animal Health Business is global leader in swine vaccines and holds strong positions in companion animal and cattle vaccines as well as in pharmaceutical specialties for animal use. The company researches and develops therapeutic solutions for animals in the US, Germany, China, Mexico and Japan. In its research-driven Animal Health business, Boehringer Ingelheim continually invests around 12% of net sales of the Animal Health business in R&D.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative “Making More Health” while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.
In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
Intended audiences: This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
1) Based on Doses Sold, August 2016, Data on file
2) Based on net sales, MAT Q2 2016, Data on file